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BACKGROUND: Recurrent mutations in the Speckle-Type POZ Protein (SPOP) gene occur in up to 15% of prostate
cancers. However, the frequency and features of cancers with these mutations across different populations is
unknown. OBJECTIVE: To investigate SPOP mutations across diverse cohorts and validate a series of assays
employing high-resolution melting (HRM) analysis and Sanger sequencing for mutational analysis of formalin-fixed
paraffin-embedded material. DESIGN, SETTING, AND PARTICIPANTS: 720 prostate cancer samples from six inter-
national cohorts spanning Caucasian, African American, and Asian patients, including both prostate-specific
antigen–screened and unscreened populations, were screened for their SPOP mutation status. Status of SPOP
was correlated to molecular features (ERG rearrangement, PTEN deletion, and CHD1 deletion) as well as clinical
and pathologic features. RESULTS AND LIMITATIONS: Overall frequency of SPOP mutations was 8.1% (4.6% to
14.4%), SPOP mutation was inversely associated with ERG rearrangement (P < .01), and SPOPmutant (SPOPmut)
cancers had higher rates of CHD1 deletions (P < .01). There were no significant differences in biochemical recur-
rence in SPOPmut cancers. Limitations of this study include missing mutational data due to sample quality and
lack of power to identify a difference in clinical outcomes. CONCLUSION: SPOP is mutated in 4.6% to 14.4% of
patients with prostate cancer across different ethnic and demographic backgrounds. There was no significant
association between SPOPmutations with ethnicity, clinical, or pathologic parameters. Mutual exclusivity of SPOP
mutation with ERG rearrangement as well as a high association with CHD1 deletion reinforces SPOP mutation as
defining a distinct molecular subclass of prostate cancer.
Neoplasia (2014) 16, 14–20Introduction
Prostate cancer is a significant health burden, with 241,740 new diag-
noses and 28,170 deaths in the United States in 2012 [1]. The inability
to distinguish indolent from aggressive disease is a challenge [2]. Iden-
tification of driver lesions for specific subsets of prostate cancer could
ultimately lead to the development of biomarkers to improve prog-
nostic ability and risk stratification.
Recent advances have uncovered multiple recurrent alterations in
prostate cancer. The TMPRSS2-ERG fusion has been observed in
nearly 50% of prostate cancers [3,4].
We recently reported somatic mutations in the Speckle-Type POZ
Protein (SPOP) gene in 6% to 15% of prostate cancers [5]. SPOPmuta-
tions define a distinct subclass of prostate cancer: SPOP mutations and
ETS rearrangements are mutually exclusive; SPOP mutant (SPOPmut)
prostate tumors generally lack lesions in the phosphatidylinositide
3-kinase (PI3K) pathway, and they are also independent of mutations
in the tumor suppressor gene TP53 [5–7].
Although the recurrent nature of SPOP mutations is clear, less is
known about the frequency of SPOP mutations across different
ethnicities and screening practices, the associations with clinical and
pathologic characteristics, and the effects on patient outcomes. This
study represents the largest multi-institutional study to date investi-
gating these associations with SPOPmutations across different cohorts.
In addition, detection of SPOP mutations in older well-annotated
archival prostate cancer samples represents a technical challenge.
Formalin fixation of tissue followed by paraffin embedding (FFPE)
is widely used; however, analysis of nucleic acid from FFPE material
is difficult due to cross-linking between nucleic acid and proteins [8].
The tissue heterogeneity in prostate cancer samples can dilute thesignal of tumor-associated mutations with benign wild-type contami-
nation and make the detection of point mutations difficult.
In an effort to overcome these challenges, we developed a series of
assays employing high-resolution melting (HRM) analysis, which
relies on alterations in the melting curve of mutated nucleic acids,
and Sanger sequencing [9–11]. We optimized the HRM assay as a
high sensitivity pre-screening tool, followed by Sanger sequencing for
specific confirmation of mutations. Finally, we employed a next-
generation sequencing approach on a small subset of samples to
determine if massively parallel sequencing could rescue samples con-
sidered assay failures using the HRM-Sanger methods.
Materials and Methods
Patient Populations
Table 1 lists the clinical, pathologic, and survival data according
to each cohort. In total, prostate cancer samples from 996 patients
[radical prostatectomy (RP), transurethral resection of the prostate
(TURP), or metastatic biopsies] were examined. Of the 996 patients,
720 samples had DNA of sufficient quality and were screened for
their SPOP status. Cohorts included patients from Memorial Sloan-
Kettering Cancer Center (MSKCC), cohort from Kyungpook National
University School of Medicine, Korea (Korean), African American
cohort from New York-Presbyterian Hospital (AA), Weill Cornell
Medical College (WCMC) cohorts, and University Hospital of Zurich
(USZ), as well as the Swedish watchful waiting cohort (SWWC). A
detailed description about each individual cohort can be found in the
Supplementary Materials and Methods. Samples were categorized into
SPOP wild type (SPOPwt) and SPOPmut and analyzed for correlation
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expertise in genitourinary pathology reviewed the archival material at
each participating institution. Institutional Review Board approval
was obtained at all participating sites.
Patient-Related Variables
All clinical and pathologic data were prospectively collected by
each individual center, including information on patient age, pre-
operative prostate-specific antigen (PSA) level, Gleason score, patho-
logic stage, surgical margin status, and biochemical recurrence (BCR).
Detailed description of staging and BCR as well as PSA characteri-
zation can be found in the Supplementary Materials and Methods.
For a subset of 118 unselected prostate cancers from the WCMC
cohort, 15 morphologic features of prostate cancer were assessed
(Qiagen, Hilden, Germany). A detailed description of the morpho-
logic features as well as the process of review is described in the
Supplementary Materials and Methods.DNA Extraction
DNA for the AA and Korean cohorts and SWWC was extracted
from tissue cores using a Qiagen BioRobot Universal System. Detailed
description of the protocol can be found in the Supplementary
Materials and Methods. Detailed description of DNA extraction for
the cohorts from WCMC, MSKCC, as well as Zurich have been pre-
viously described [5,12,13].
Targeted Enrichment for SPOP Exons 6 and 7 and
HRM Analysis
The mutational screening assay involves an initial pre–polymerase
chain reaction (PCR) amplification step to enrich the target region
followed by an HRM screen and Sanger sequencing. PCR assay setup,
as well as cycling conditions, HRM assay, and analysis are described
in the Supplementary Materials and Methods.
Sanger Sequencing
PCR products were purified using Qiagen PCR purification kit
and eluted as per the manufacturers’ instructions and sent for SangerFigure 2. Schematic overview of the SPOP gene and localization of
(MATH) and broad complex, tramtrack and bric-a-brac (BTB), and the s
recurrence are shown. The proportion of the colors in bars indicates
(orange), MSKCC (light blue), Zurich (purple), Swedish (green), Korean
the cohort is shown next to the color coding system.sequencing a minimum of three times to confirm the mutation status.
(For a complete list of primers, see Table W1.)Fluorescence In Situ Hybridization and Immunohistochemistry
Fluorescence In Situ Hybridization (FISH) methods to detect
TMPRSS2-ETS gene fusions have been previously described
[3,14]. We used ERG break-apart FISH assays to confirm gene re-
arrangement on the DNA level [15]. To assess the status of PTEN, we
used a locus-specific probe and a reference probe, as previously described
[16], and a similar approach was used to detect CHD1 deletions. The
sequences of all FISH probes are listed in Table W1. ERG expression
was assessed by immunohistochemistry, as previously described [17].DNA Capture, Library Preparations, and MiSeq Runs
A customized TrueSeq amplicon kit was designed by using Illumina
DesignStudio, and the library preparation was performed as sug-
gested by the manufacturer. More information about the design and
the library preparation can be found in the Supplementary Materials
and Methods.Alignment and Analysis
Reads were aligned independently to the human genome reference
sequence (GRC37/hg19) using a Smith-Waterman mode BWA
[18] to maximize the number of reads aligned to the genome. An in-
house tool was then used to determine the genotype of the locations
of SPOP.Statistical Analysis
Results were expressed as a contingency table to show associa-
tion between SPOP status with clinical and pathologic variables
along with available molecular data (Table 3). Differences were
considered statistically significant at P < .05. All statistical analyses
were performed with Stata SE, version 11.0 (StataCorp, College
Station, TX).mutations. The two protein domains, meprin and TRAF homology
pecific amino acid positions harboring the alterations and its relative
the abundance of the mutation in each of the six cohorts, WCMC
(red), and AA (dark blue). The overall frequency of mutated SPOP in
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Performance of HRM Assay
In this study, we screened 996 samples from six independent cohorts:
WCMC, AA, Korean, MSKCC, Zurich, and SWWC for their SPOP
status. Of 996 samples, we were able to successfully evaluate SPOP
status in 720 samples (72.3%), which were classified into 662 SPOPwt
and 58 SPOPmut samples. A flowchart of sample testing is shown
in Figure 1. To determine the sensitivity of HRM and reliability for
annotating wild-type samples, 100 samples with wild-type HRM results
(no shift) were subsequently Sanger sequenced. All 100 samples were
SPOPwt. A dilution series of plasmid DNA showed that less than 5%
of SPOPmutDNAwas sufficient for a notable shift in the melting curve
(Figure W1).
A subset of 22 samples was flagged positive by HRM but could not
be validated by Sanger sequencing due to assay failure; deep sequenc-
ing of those samples was attempted on the MiSeq platform; however,
overall read quality was poor and we therefore excluded those samples
from the study. With an overall coverage of 98.7% of the SPOPexome and an average number of 591,242 mapped reads for 10 control
samples, 6 FFPE material and 4 fresh frozen, the efficiency of the
capture assay and the sequencing was demonstrated.SPOP Mutation across Cohorts
SPOPmutations were detected in 58/720 evaluable cases (8.1%) tar-
geting all previously detected mutations in prostate cancer. Consistent
with previous results, the most frequently mutated residue was F133
(50%) followed by Y87 (15%), W131 and F102 (9%), F125 (3%),
and K129, F104, and K135 (2%). All mutations were missense and
clustered in the substrate bindingMATHdomain (Figure 2).Mutations
at F104 and K135 have not been previously described.Association of SPOP Mutation with Clinicopathologic
Characteristics and Outcomes
The clinicopathologic characteristics of the 996 patients are sum-
marized in Table 1. Overall, the rate of SPOP mutation was 8.1%
(4.6%-14.4%, see Table 2). The AA cohort had the lowest rate of
SPOP mutations (4.6%), and the highest rate was in the WCMC
cohort (14.4%), but there were no significant differences between
cohorts (P = .14). Patients with SPOP mutations had no significant
differences in Gleason grade and rates of BCR (P = .26 and P = .18,
respectively; Table 3). In a separate sub-analysis, those who had
treatment for their prostate cancer by RP (N = 911) were compared
to those who received only palliative treatment (i.e., TURP; N =
197), and no significant differences were noted in frequency of
SPOP mutations (8.75 vs 6.1%, P = .40). Patients with mutant SPOP
had a median time to BCR of 15 months compared to 18 months for
SPOPwt (P = .30). There were no significant differences noted in age,
preoperative PSA, lymph node positivity, or pathologic stage accord-
ing to SPOP mutation status. There were also no noted differences in
survival according to SPOP status (P = .78). There were no significant
associations noted with SPOP mutations on univariable or multi-
variable Cox regression models for relapse-free survival, cancer-specific
survival, and overall survival (P = .57, .62, .75, respectively).Association of SPOP Mutations with Morphologic Features of
Prostate Cancer
No morphologic features were associated with positive SPOPmut sta-
tus. Cribriform morphology was present in 64% of SPOPmut compared
to 18% in nonmutants (P = .08). Foamy gland morphology showed a
significant negative association with SPOPmut, with 18% of SPOPmut
cases exhibiting this feature compared to 72% of control cases (P = .03).
However, when this P value was adjusted to account for multiple
comparisons (Bonferroni method), the statistical significance was lost.Table 2. Molecular Alterations by Cohort.No. of Evaluable Samples SPOP ERG PTEN CHD1Wild Type Mutant Wild Type Positive Wild Type Deletion Wild Type DeletionAfrican American 88 84 (95.4%) 4 (4.6%) 66 (75.0%) 22 (25.0%) 78 (91.8%) 7 (8.2%) NA NA
Korean 87 81 (93.1%) 6 (6.9%) 55 (70.5%) 23 (29.5%) 53 (82.8%) 11 (17.2%) NA NA
Swedish 99 93 (93.9%) 6 (6.1%) 79 (79.8%) 20 (20.2%) NA NA 52 (82.5%) 11 (17.5%)
Zurich 241 222 (92.1%) 19 (7.9%) 80 (45.5%) 96 (54.5%) 93 (51.7%) 87 (48.3%) NA NA
MSKCC 80 75 (93.7%) 5 (6.3%) 38 (47.5%) 42 (52.5%) 75 (93.8%) 5 (6.3%) 67 (87.0%) 10 (13.0%)
WCMC 125 107 (85.6%) 18 (14.4%) 65 (61.9%) 37 (35.2%) 82 (81.2%) 19 (18.8%) 36 (70.6%) 15 (29.4%)Table 3. Demographics and Molecular Changes by SPOP Mutation.WT +SPOP P ValueN (%) 662/720 (91.9%) 58/720 (8.1%)
Median age 65 (34-89) 64 (46-84) 0.49
Median PSA 7.1 7.4 0.65
Gleason grade 0.26
6 97 (15.9%) 4 (7.3%)
3 + 4 230 (37.7%) 20 (36.4%)
4 + 3 132 (21.6%) 16 (29.1%)
8 to 10 151 (24.8%) 15 (27.3%)Pathologic stage 0.58
pT2 298 (62.6%) 29 (70.7%)
pT3 166 (34.9%) 12 (29.3%)
pT4 12 (2.5%) 0Median follow-up time, months (range) 73 (1.9-182) 100.5 (13-160) 0.67
Positive BCR 70 (19.9%) 7 (25.9%) 0.45
Median time to BCR, months (range) 18 (1.2-139) 15 (11-55.4) 0.29
Status 0.69
NED 158 (50.8%) 10 (47.6%)
AWD 65 (20.9%) 6 (28.6%)
DOD 77 (24.8%) 4 (19.0%)
DOC 11 (3.5%) 1 (4.8%)ERG <0.01
WT 337 (59.4%) 46 (95.8%)
Positive 230 (40.6%) 2 (4.2%)PTEN 0.31
WT 350 (74.1%) 31 (81.6%)
Deletion 122 (25.9%) 7 (18.4%)CHD1 <0.01
WT 147 (85.0%) 8 (42.1%)
Deletion 26 (15.0%) 11 (57.9%)BCR indicates biochemical recurrence; AWD, alive with disease; NED, no evidence of disease;
DOD, died of disease; DOC, died of other causes; WT, wild type.
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Molecular Alterations
Across all six cohorts, the frequency of ERG rearrangement was
38.3% (range, 20.2%-54.5%), PTEN deletions 25.3% (6.3%-
48.3%), and CHD1 deletions 19.3% (13.0%-29.4%). We found
only two SPOPmut cases with an ERG rearrangement (P < .01),
consistent with previously reported mutual exclusivity [5]. There
were no significant associations between SPOP mutations and PTEN
deletions (P = .31) despite previously reported inverse association in
clinically localized disease [5]. Patients with SPOP mutations demon-
strated significantly higher rates of CHD1 deletion (57.9% vs 15.0%,
respectively, P < .01).
Discussion
This study represents the largest multi-institutional collaboration to
evaluate for SPOP mutations across different populations. In the cur-
rent study, the rate of SPOP mutations was similar across different
ethnicities and cohorts, at a rate of 8.1% of prostate cancers, rang-
ing from 4.6% in the AA cohort to 14% in the WCMC cohort. In
addition, differences in SPOP frequency might be influenced by
intratumor heterogeneity, prostate tumor density, tumor multifocality
and sample handling variations among different institutions. Method of
detection and sample quality may also play a role; next-generation
sequencing and high-quality tissue specimens will likely maximize sen-
sitivity. Finally, subclonality of certain point mutations will likely
impact detection rates. SPOP mutations have been shown to be highly
clonal [19], limiting this concern for these specific mutations, but the
heterozygous nature of SPOP mutations does impact sensitivity.
Previous studies have suggested that SPOP mutations identify a
distinct molecular subclass of prostate cancer compared to ETS
family rearrangements [5,20]. This study confirms those findings;
of 58 SPOP-mutated cases, only two showed an ERG rearrangement
in the same patient. Co-occurrence of SPOP mutation and ERG
rearrangement may be due to sampling adjacent but molecularly dis-
tinct tumor foci in the same specimen, as previously described [5], or
as a result of intratumoral heterogeneity. We also cannot exclude the
possibility that SPOP mutations and ETS rearrangement do occur
together in the same tumor cells at exceptionally low frequency.
SPOP mutations are also associated with CHD1 deletions [5,19].
In this study, 57.9% of the SPOPmut harbored CHD1 deletions.
These findings suggest that SPOP mutations may be driver lesions
in a distinct molecular subclass of prostate cancer. Across all cohorts,
we saw no significant association between PTEN deletion and SPOP
mutation. We had previously reported an inverse association between
SPOP mutation and PTEN lesions in clinically localized prostate
cancer but in a PSA-screened population of primarily Caucasian
men [5]. Previously, we observed no association between SPOP
mutation and PTEN deletions in metastatic cancer, highlighting that
the relationship between these two abnormalities is highly dependent
on the context of the specific patient cohort.
We detected no signification difference in rates or time to BCR in
relation to SPOP status. However, despite the considerable sample
size, the study was underpowered to evaluate oncologic outcomes
in relation to SPOP status: Assuming a 15% rate of BCR rate after
5 years of definitive surgical management according to recent large
studies [21–23], and assuming an overall SPOP mutation rate of
approximately 10% [5], to achieve at least 80% power to detect a sig-
nificant difference in BCR, the sample size would need to be several
thousand patients with long-term follow-up. With the establishmentof assays defined here, we can continue multi-institutional collabora-
tive efforts to identify associations of SPOP mutation with clinical
outcomes to connect molecular classification with risk stratification.
We have developed an HRM-based screening assay, which allows us
to screen samples from archival FFPE material in a high-throughput
and cost-efficient manner. This assay demonstrates high sensitivity,
reliability, and efficiency. Less than 5% mutated tumor DNA has to
be present to lead to a positive result. However, it is important to note
that no mutation calls were made solely based on HRM; all potential
mutations were verified by Sanger sequencing. Sanger sequencing has a
sensitivity of roughly 20% [24], making the HRM assay considerably
more sensitive but difficult to validate. Samples showing a shift on
HRM but no mutation by sequencing were classified as assay failures
and excluded to rule out false-negative calls. One concern about
archival material is the potential poor quality of the DNA. Most likely
poor DNA quality was the reason for the assay failure rate (28.3% of all
samples). Assay failure could not be rescued by next-generation sequenc-
ing, reinforcing that the sample characteristics were likely more impor-
tant than the assay characteristics.
Our study is the first to examine morphologic features of SPOPmut
prostate cancer. Although the clinical significance of SPOPmut status
is yet to be established, we sought to assess if SPOPmut prostate cancer
could be recognized histologically. When subsets of SPOPmut and
SPOPwt cases with similar Gleason score and pathologic stage were
compared, no morphologic features were associated with positive
SPOPmut status.
In conclusion, we have shown that SPOP is mutated in 4.6% to
14.4% of prostate cancers in six cohorts with different ethnic and
demographic backgrounds. There was no significant difference in
SPOP mutation frequency among cohorts. Mutual exclusivity of
mutated SPOP and ERG rearrangement as well as high correlation
of SPOP mutation with deletion of CHD1 across different cohorts
and ethnicities reinforces SPOP mutation as defining a distinct
subclass of prostate cancer. Further studies, potentially with large
numbers of patients, will be needed to determine the impact of
SPOP mutation on clinical outcome.Acknowledgments
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Supplementary Materials and Methods
Patient Population and Patient-Related Variable
Tumor staging and grading were standardized to the 2002 American
Joint Committee on Cancer recommendations. After RP, patients
were followed until death for disease recurrence. BCR was defined as
a serum PSA level > 0.2 ng/ml on more than two consecutive occa-
sions for the WCMC and AA cohorts. BCR in the Zurich cohort
was defined as any increase in postoperative PSA > 0.1 ng/ml after
achieving a PSA nadir < 0.1 ng/ml, while the Korean cohort defined
BCR as any postoperative PSA > 0.2 ng/ml after achieving a PSA
nadir < 0.1 ng/ml. Follow-up data on BCR was present in 537 patients
(54.0%), and survival data were present on 226 patients (22.6%).Swedish Watchful Waiting Cohort
The SWWC, as described previously [25], consisted of non–PSA-
screened men with localized prostate cancer diagnosed by TURP and
managed with watchful waiting. A subset of this population (141 pa-
tients) had FFPE specimens that were satisfactory for evaluation, of
which 99 had DNA of sufficient quality and were included in this
study. SPOP status was determined by performing HRM assay fol-
lowed by Sanger sequencing. ERG rearrangement, PTEN deletions,
and CHD1 deletions were detected by FISH.Korean Cohort
The Korean cohort consists of 127 consecutive patients with prostate
cancer treated by robotic-assisted laparoscopic prostatectomy (RALP) at
Kyungpook National University School of Medicine. The majority of
these patients were found to have prostate cancer because of obstructive
lower urinary tract symptoms; PSA is not routinely used as a screening
tool in South Korea. Of the 127 patients, 87 had DNA of sufficient
quality for evaluation. Slides of FFPE tissue from RALP were reviewed
by study pathologists to confirm diagnosis and the pathologic charac-
teristics, including Gleason grade, surgical margin, and pathologic
stage. SPOP status was screened by performing HRM assay followed
by Sanger sequencing. ERG status was annotated by immunohisto-
chemistry and FISH. PTEN deletions were also identified by FISH.USZ Cohort
FFPE prostate tissues from 421 consecutive men who underwent
either RP (336), TURP (56), or metastasis (29) collection were ob-
tained at the University Hospital of Zurich between 1993 and 2007
[12]. Slides of FFPE tissue were reviewed by study pathologists to
confirm diagnosis and the pathologic characteristics, including Gleason
grade, surgical margin, and pathologic stage. Of the 421 specimens,
251 were of sufficient quality to be analyzed. SPOP status was screened
by performing HRM assay followed by Sanger sequencing. ERG re-
arrangements, CHD1 deletions, and PTEN deletions were determined
by performing FISH.MSKCC Cohort
A total of 218 fresh frozen tumor samples were obtained from
patients treated by RP at MSKCC, as previously described [13]. Eighty
patients had DNA that could be reliably analyzed for this study. There
were no significant differences in Gleason grade, stage, or clinical out-
comes between the 80 cases fromMSKCC that had evaluable DNA for
SPOP and the 138 cases that did not have evaluable DNA. The per-centage of tumor tissue versus normal tissue was at least 70% to be
extracted [13]. SPOP status was identified by Sanger sequencing.
ERG rearrangements were inferred using outlier mRNA expression,
and PTEN and CHD1 deletions were determined from array compara-
tive genomic hybridization (CGH), as previously described [13].WCMC Cohort
Tumors for the WCMC cohort were collected from 125 patients
undergoing RALP from 2007 to 2010 by one single surgeon at a single
institution. Cores in areas with high tumor density have been taken with
an overall average of at least 60% tumor material. All African American
patients were excluded from the WCMC cohort and grouped into a
separate cohort. SPOP status was collected from previously reported
whole exome data, RNA-Seq data, as well as Sanger sequencing [5].
We excluded four SPOPmut cases that showed inconsistent results be-
tween detection methods. ERG status was determined using FISH and
immunohistochemistry (IHC); CHD1 deletions and PTEN deletions
were identified using FISH and CGH as previously described [5].AA Cohort
Archival RP from 105 consecutive self-identified African American
men were obtained at WCMC between 2001 and 2009, of which 88
had evaluable DNA. SPOP status was screened by performing HRM
assay followed by Sanger sequencing. ERG expression was deter-
mined by IHC, and identification of ERG rearrangement and PTEN
deletion was done by FISH. Molecular and clinical details of this
cohort have been reported elsewhere [26].
Determining if SPOPmut Prostate Cancer Is Associated
with a Morphologic Phenotype
A subset of 118 unselected prostate cancers from the WCMC was
assessed. This group included 11 SPOPmut cases. Blinded to muta-
tion status, two reviewers at WCMC assessed all prostatectomy slides
from these 11 SPOPmut cancers and 11 SPOPwt cases with similar
Gleason score and pathologic stage. Each prostatectomy specimen
was assessed for the presence or absence of 15 morphologic features
of prostate cancer: intraductal spread, cribriform morphology, blue-
tinged mucin, crystalloids, high nucleocytoplasmic ratio, macro-
nucleoli, foamy gland features, collagenous micronodules, small cell/
neuroendocrine differentiation, perineural invasion, extraprostatic
extension, signet ring–like cell features, ductal morphology, glomerula-
tions, and comedonecrosis. Statistical analysis was performed to look
for significant associations between morphology and SPOPmut status.DNA Extraction
Citrosolve (400 μl) was added to each well of a 96-well plate. The
plate was then placed on a shaking pad, followed by incubation on a
heat plate for 10 minutes, placed back on the shaking pad, and repeated
for a total of three times. After the three cycles, the citrosolve was
removed and the samples received two 400 μl of ethanol washes. After
a 1-hour drying step, 300 μl of AL tissue lysis buffer was added in
addition to 20 μl of proteinase K solution for an overnight incubation.
Two additional sets of 20 μl of proteinase Kwere added if cores were still
visible, and each time incubated at 55°C for 3 hours with intervals of
shaking. After digestion, 300 μl of lysis buffer and 600 μl of ethanol were
added to the lysate and the samples were transferred to a filter column.
AW1 andAW2wash buffers with two doses of 96% ethanol were added
to purify the samples. DNA was then eluted in two steps in 50 μl of
AE buffer by centrifugation. DNA was quantified using the Nano-
drop spectrophotometer. Samples with a DNA concentration of
20 to 50 ng/μl or above were included in the study. DNA purity
was determined by measuring UV absorbance [15]. DNA extraction
from the WCMC cohort [5] and MSKCC cohort [15] has been pre-
viously described. DNA from patients of the hospital of Zurich was
extracted by using the blood and tissue kit (Qiagen) as suggested by
the manufacturer.Targeted Enrichment for SPOP Exons 6 and 7
The pre-PCR reactions were performed in 30-μl volumes. For
the exon 6 assay, 1 μl of patient DNA (30-80 ng), 2 μl of working
primer solution (forward + reverse, 3 μM concentration), 2.4 μl of
50 mM MgCl2, 4 μl of 10 mM deoxyribonucleotide (dNTP) solu-
tion (Invitrogen, Carlsbad, CA), 2 μl of 1.5 mM High-Fidelity PCR
Buffer (Thermo Scientific, Waltham, MA), and 17.8 μl of sterile
water were used. For the exon 7 assay, the process was the same as
for exon 6 except for the addition of 11.8 μl of sterile water and 6 μl of
5× combinatorial enhancer solution (CES) enhancer solution [27].
Pre-PCR was performed on Eppendorf Mastercycler Pro. Optimized
cycling conditions used for both assays are given as follows: initial
activation step at 98°C for 1 minute, followed by 30 cycles of 95°C
for 5 seconds, 60°C for 10 seconds, and 72°C for 30 seconds. After
a final step of 72°C for 30 seconds, samples were held at 4°C. (For
complete list of primers, see Table W1.)HRM Analysis
Pre-PCR products were diluted 1:100 with sterile water. Samples
were run in triplicate on the LightCycler 480 II (Roche Diagnostics,
Basel, Switzerland). A total reaction volume of 10 μl was used, which
consisted of 1 μl of diluted pre-PCR products and 3 μM forward
and reverse HRM primers, 5 μl of High Resolution Melting Master
Mix (from Roche), 1 μl (exon 6 assay) or 1.4 μl (exon 7 assay) of
25 mM MgCl2 plus 2 μl (exon 6 assay) or 1.6 μl (exon 7 assay) of
PCR-grade water.
HRM conditions used were given as follows: An activation step of
10 minutes at 95°C is followed by 30 cycles of 10 seconds at 55°C
and 72°C for 30 seconds. Before the HRM, a heteroduplex formingstep that involves heating the PCR products to 95°C for 1 minute and a
rapid cooling to 45°C for 1 minute is performed. HRM was performed
from 72°C to 95°C at a temperature gradient of 1°C per second, acquir-
ing 30 data points per °C. (For complete list of primers, see Table W1).
This assay targets two exons of the SPOP gene containing all previously
detected mutations in prostate cancer (amino acids 80 to 106 and
amino acids 120 to 140).
The melting curves were normalized at the pre-melt (100% fluo-
rescence) and post-melt (0% fluorescence) stages using gene scanning
software (Roche) [28]. Further assay details and cycling conditions
can be found in the Supplementary Materials and Methods. Seven
controls were run in each assay along with 96 samples on a 384-well
plate. Normalization of the melting curves was done using these con-
trols. The controls used were five known heterozygous mutations
F133V, F133C, K129E, F102C, and Y87C and two known wild-
type controls (one for exon 6 and one for exon 7). The average size
of 50 to 150 bp of the targeted fragment is notable, as the use of
archival material, such as DNA from FFPE material, can show a high
degree of degradation. Every sample that showed a notable shift in
the melting curve was sent off for Sanger sequencing to confirm and
further specify its alteration.
To determine the assay sensitivity, plasmid DNA of mutated
SPOP was mixed with plasmid DNA of wild-type SPOP in differ-
ent ratios. This allows us to investigate the sensitivity in the most
accurate manner and leads to the highest possible sensitivity under
best conditions.
DNA Capture, Library Preparations, and MiSeq Runs
By using the Illumina DesignStudio application (http://www.
illumina.com/applications/designstudio.ilmn), we designed a custom-
ized TrueSeq amplicon kit to cover all exons of SPOP (∼3.5 kb). Forty-
six amplicons with an average size of 174nt (±6) were designed. All
samples were run on one lane of MiSeq that generated 13 Mb paired
end reads (2 × 250 bp) for a total of ∼6.5 Gb.
The library preparation was performed as suggested by the man-
ufacturer (http://supportres.illumina.com/documents/myillumina/
b718c350-b3b2-4234-b71a-0b832f14cda3/truseq_custom_amplicon_
libraryprep_ug_15027983_b.pdf). We considered samples passing qual-
ity control (QC) if they had more than 250 ng in 5 μl, quantified by
Qubit, and aminimal fragment size of 45 bp, determined by Bioanalyzer.
Table W1. Sequence of Primers.SPOP GeneFigure W1. Sensitivity of HRM
consists of 50%mutant and 5
red of 60% mutant and 40%Primer Name. The HRM curves for a serial dilutio
0% wild-type DNA, gray of 25%mu
wild-type DNA, blue of 1% mutantSequence (5′-3′)n of mutated and wild-type DNA are shown. The purple
tant and 75% wild-type, green of 10%mutant and 90% w
and 99% wild-type DNA, and brown of 100% wild-typeAmplicon Size (bp)Pre-PCR
Exon 7 SPOP_E7_PPCR_R AGT TGT GGC TTT GAT CTG GTT 240
Exon 7 SPOP_E7_PPCR_F ACT CAT CAG ATC TGG GAA CTG C
Exon 6 SPOP_E6_PPCR_F ACC CAT AGC TTT GGT TTC TTC TCC C 170
Exon 6 SPOP_E6_PPCR_R TAT CTG TTT TGG ACA GGT GTT TGC GHRM
Exon 7 SPOP_E7_HRM_R TTT CCC ACC CCA GAG AGT 102
Exon 7 SPOP_E7_HRM_F GTT GGC CTC ATC CAA AAG AA
Exon 6 SPOP_E6_HRM_F TCT TCT CCC TTG GCA TTC AG 123
Exon 6 SPOP_E6_HRM_R CCC CAA AGG GTT AGA TGA AGASequencing
Exon 7 SPOP_E7_PPCR_F ACT CAT CAG ATC TGG GAA CTG C
Exon 6 SPOP_E6_PPCR_R TAT CTG TTT TGG ACA GGT GTT TGC GThe sequence of primers was used for the pre-PCR, HRM, as well as Sanger sequencing.melting curve
ild-type DNA,
DNA.
